NCT05311618 2024-04-01
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Phase 1 Unknown
NGM Biopharmaceuticals, Inc
Kineta Inc.
Portland VA Medical Center
IRCCS San Raffaele